Developer docs
API playgroundTry for free, no card

Search company profiles

Celerion

Full company profile

uuid0004ei1

Namestring
Celerion
Legal namestring
Celerion Holdings, Inc.
Websiteurl
celerion.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Celerion is a privately held contract research organization (CRO) specializing in early-phase clinical drug development for pharmaceutical and biotechnology sponsors. Founded with operations tracing back more than 50 years and headquartered in Lincoln, Nebraska, the company runs 1,001–5,000 employees across facilities in Lincoln, Phoenix, Zurich, and Belfast. Its core services span clinical pharmacology (first-in-human, proof-of-concept, and dose-escalation studies), bioanalytical sciences (method development, validation, and sample analysis), cardiovascular safety assessment (ECG and Holter monitoring), and cGMP-compliant US pharmacy services for Phase 1 investigational drugs. The operating model is an integrated clinical-and-laboratory platform — combining Phase 1 clinical research units with in-house bioanalytical labs and a dedicated senior cardiology function under Dr. Steven Evans — which the company's PE sponsor cites as a differentiator versus single-service CROs.

Celerion serves two primary customer segments — large and mid-size pharmaceutical companies and biotechnology companies — addressing pain points around escalating R&D costs, biologic drug development complexity, and the need for specialized early-phase expertise. Customer relationships are driven through enterprise B2B sales, with marketing supported by industry conferences, scientific publications, and direct business development. The company was acquired by H.I.G. Capital in November 2022, which supported commercial, operational, and technology investments that materially expanded the clinical and laboratory footprint; in June 2026, H.I.G. sold Celerion to funds affiliated with THL Partners for approximately $1.8 billion, with the acquirer citing the integrated platform as well-positioned for growing drug development complexity.

The revenue model is professional services: project-based, quote-driven contracts for clinical trials, bioanalytical testing, and specialized safety assessments, with pricing not publicly disclosed. Recent operating actions include Belfast operations relocating to Queen's University Belfast's £64m iREACH Health Clinical Research Innovation Center (Feb 2025), expansion of US on-site cGMP-compliant pharmacy services, and an SBTi Net-Zero Standard commitment. Celerion is currently a portfolio company of THL Partners, with majority ownership held through THL's Fund IX.

Short descriptiontext

Celerion is a privately held clinical research organization (CRO) providing integrated early-phase clinical pharmacology, bioanalytical, and cardiovascular safety services to pharmaceutical and biotechnology sponsors across North America, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLincoln, United States
HQ citystring
Lincoln
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical pharmacology services, bioanalytical testing, early-phase clinical trials, cardiovascular safety assessment, contract research organization
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Clinical Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Contract research organization providing clinical pharmacology and early-stage drug development services to pharmaceutical and biotechnology clients. Revenue is generated through project-based contracts for clinical trials, bioanalytical testing, and specialized safety assessment services.

citybiz.co
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celerion is a contract research organization (CRO) providing early-phase clinical pharmacology and bioanalytical sciences services for pharmaceutical and biotechnology drug development programs. The company operates integrated clinical research units and laboratory facilities delivering first-in-human studies, dose-escalation trials, bioanalytical method development and validation, sample analysis, and specialized cardiovascular safety assessment including ECG and Holter monitoring.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Celerion is a clinical research organization providing integrated clinical pharmacology and bioanalytical sciences services for early-stage drug development. The company operates a platform combining clinical research units with laboratory capabilities, offering services spanning first-in-human studies, bioanalytical method development and validation, and specialized cardiovascular safety assessment. The portfolio includes Phase 1 clinical trial services, cGMP-compliant pharmacy services for investigational drugs, and specialized cardiac safety monitoring including ECG and Holter analysis.

Product and service1 record
1Clinical Pharmacology Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-24
Description

Celerion expanded UK Phase 1 clinical research operations by relocating to Queen's University Belfast's iREACH Health – Clinical Research Innovation Center. This partnership supports advancement of clinical trial development in key healthcare areas. The new facility represents a £64m complex.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the largest global CRO with full Phase I–IV coverage plus real-world evidence and technology platforms. It is a broad incumbent that competes with Celerion in early-phase clinical pharmacology and bioanalytical services while offering much broader downstream capabilities.

TypeDirect peer
Description

Charles River is a leading CRO with strong preclinical and early-phase clinical capabilities, including bioanalytical and safety assessment services. It directly overlaps with Celerion in clinical pharmacology and laboratory services for pharma/biotech sponsors.

TypeBroad incumbent
Description

Labcorp Drug Development is a global CRO and central laboratory operator offering early through late-phase clinical research. Its central lab and early development services directly overlap with Celerion's bioanalytical and Phase 1 offerings.

TypeBroad incumbent
Description

ICON is a global CRO providing Phase I–IV services, bioanalytical labs, and post-approval research. It competes with Celerion for early-phase clinical pharmacology and bioanalytical mandates from pharma and biotech sponsors.

TypeBroad incumbent
Description

Parexel is a global CRO offering early-phase clinical research, biostatistics, regulatory, and post-approval services. It directly competes with Celerion in early-phase clinical pharmacology and bioanalytical sciences.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-size CRO focused on early-phase through post-approval clinical research, with strong bioanalytical capabilities. Its positioning in Phase 1 clinical pharmacology and bioanalytical sciences closely mirrors Celerion's.

TypeDirect peer
Description

Medpace is a mid-size, full-service CRO with growing early-phase capabilities. It targets small and mid-size biopharma sponsors similar to Celerion's customer base and competes for Phase 1 and bioanalytical work.

TypeBroad incumbent
Description

Syneos Health is a global biopharmaceutical solutions organization offering clinical development and bioanalytical services. It overlaps with Celerion in early-phase clinical research for pharma and biotech sponsors.

TypeEmerging player
Description

BioAgilytix is a bioanalytical-focused CRO specializing in PK, immunogenicity, and biomarker assays. It directly overlaps with Celerion's bioanalytical sciences platform and competes for similar pharma/biotech sponsors.

TypeEmerging player
Description

Frontage Laboratories is a CRO providing bioanalytical, preclinical, and early clinical development services. It overlaps with Celerion in bioanalytical sciences and Phase 1 clinical pharmacology, with strong US-China operations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celerion

Clinical Research Servicescelerion.com

Celerion is a privately held clinical research organization (CRO) providing integrated early-phase clinical pharmacology, bioanalytical, and cardiovascular safety services to pharmaceutical and biotechnology sponsors across North America, Europe, and Asia.

What Celerion does

Celerion is a privately held contract research organization (CRO) specializing in early-phase clinical drug development for pharmaceutical and biotechnology sponsors. Founded with operations tracing back more than 50 years and headquartered in Lincoln, Nebraska, the company runs 1,001–5,000 employees across facilities in Lincoln, Phoenix, Zurich, and Belfast. Its core services span clinical pharmacology (first-in-human, proof-of-concept, and dose-escalation studies), bioanalytical sciences (method development, validation, and sample analysis), cardiovascular safety assessment (ECG and Holter monitoring), and cGMP-compliant US pharmacy services for Phase 1 investigational drugs. The operating model is an integrated clinical-and-laboratory platform — combining Phase 1 clinical research units with in-house bioanalytical labs and a dedicated senior cardiology function under Dr. Steven Evans — which the company's PE sponsor cites as a differentiator versus single-service CROs.

Celerion serves two primary customer segments — large and mid-size pharmaceutical companies and biotechnology companies — addressing pain points around escalating R&D costs, biologic drug development complexity, and the need for specialized early-phase expertise. Customer relationships are driven through enterprise B2B sales, with marketing supported by industry conferences, scientific publications, and direct business development. The company was acquired by H.I.G. Capital in November 2022, which supported commercial, operational, and technology investments that materially expanded the clinical and laboratory footprint; in June 2026, H.I.G. sold Celerion to funds affiliated with THL Partners for approximately $1.8 billion, with the acquirer citing the integrated platform as well-positioned for growing drug development complexity.

The revenue model is professional services: project-based, quote-driven contracts for clinical trials, bioanalytical testing, and specialized safety assessments, with pricing not publicly disclosed. Recent operating actions include Belfast operations relocating to Queen's University Belfast's £64m iREACH Health Clinical Research Innovation Center (Feb 2025), expansion of US on-site cGMP-compliant pharmacy services, and an SBTi Net-Zero Standard commitment. Celerion is currently a portfolio company of THL Partners, with majority ownership held through THL's Fund IX.

Celerion firmographics

Firmographics
Name
Celerion
Legal name
Celerion Holdings, Inc.
Website
https://celerion.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Celerion is a privately held clinical research organization (CRO) providing integrated early-phase clinical pharmacology, bioanalytical, and cardiovascular safety services to pharmaceutical and biotechnology sponsors across North America, Europe, and Asia.
Ownership category
akta.pro rank

Celerion industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Clinical pharmacology services
  • Bioanalytical testing
  • Early-phase clinical trials
  • Cardiovascular safety assessment
  • Contract research organization

Where Celerion is headquartered

Location

Headquarters

HQ city
Lincoln
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Celerion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Others

Revenue model

  1. Clinical Research Services: Contract research organization providing clinical pharmacology and early-stage drug development services to pharmaceutical and biotechnology clients. Revenue is generated through project-based contracts for clinical trials, bioanalytical testing, and specialized safety assessment services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Celerion product offering

Product offering

Core offering

Celerion is a contract research organization (CRO) providing early-phase clinical pharmacology and bioanalytical sciences services for pharmaceutical and biotechnology drug development programs. The company operates integrated clinical research units and laboratory facilities delivering first-in-human studies, dose-escalation trials, bioanalytical method development and validation, sample analysis, and specialized cardiovascular safety assessment including ECG and Holter monitoring.

Product overview

Celerion is a clinical research organization providing integrated clinical pharmacology and bioanalytical sciences services for early-stage drug development. The company operates a platform combining clinical research units with laboratory capabilities, offering services spanning first-in-human studies, bioanalytical method development and validation, and specialized cardiovascular safety assessment. The portfolio includes Phase 1 clinical trial services, cGMP-compliant pharmacy services for investigational drugs, and specialized cardiac safety monitoring including ECG and Holter analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Pharmacology Services

Companies that use Celerion

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Celerion technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Celerion partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • iREACH Health (Queen's University Belfast)coreStrategic or Co-development Partner · 24 February 2025Celerion expanded UK Phase 1 clinical research operations by relocating to Queen's University Belfast's iREACH Health – Clinical Research Innovation Center. This partnership supports advancement of clinical trial development in key healthcare areas. The new facility represents a £64m complex.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Celerion competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the largest global CRO with full Phase I–IV coverage plus real-world evidence and technology platforms. It is a broad incumbent that competes with Celerion in early-phase clinical pharmacology and bioanalytical services while offering much broader downstream capabilities.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a global CRO and central laboratory operator offering early through late-phase clinical research. Its central lab and early development services directly overlap with Celerion's bioanalytical and Phase 1 offerings.
  • ICON plc: ICON is a global CRO providing Phase I–IV services, bioanalytical labs, and post-approval research. It competes with Celerion for early-phase clinical pharmacology and bioanalytical mandates from pharma and biotech sponsors.
  • Parexel International: Parexel is a global CRO offering early-phase clinical research, biostatistics, regulatory, and post-approval services. It directly competes with Celerion in early-phase clinical pharmacology and bioanalytical sciences.
  • Syneos Health: Syneos Health is a global biopharmaceutical solutions organization offering clinical development and bioanalytical services. It overlaps with Celerion in early-phase clinical research for pharma and biotech sponsors.

Direct peers

  • Charles River Laboratories: Charles River is a leading CRO with strong preclinical and early-phase clinical capabilities, including bioanalytical and safety assessment services. It directly overlaps with Celerion in clinical pharmacology and laboratory services for pharma/biotech sponsors.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO focused on early-phase through post-approval clinical research, with strong bioanalytical capabilities. Its positioning in Phase 1 clinical pharmacology and bioanalytical sciences closely mirrors Celerion's.
  • Medpace: Medpace is a mid-size, full-service CRO with growing early-phase capabilities. It targets small and mid-size biopharma sponsors similar to Celerion's customer base and competes for Phase 1 and bioanalytical work.

Emerging players

  • BioAgilytix Labs: BioAgilytix is a bioanalytical-focused CRO specializing in PK, immunogenicity, and biomarker assays. It directly overlaps with Celerion's bioanalytical sciences platform and competes for similar pharma/biotech sponsors.
  • Frontage Laboratories: Frontage Laboratories is a CRO providing bioanalytical, preclinical, and early clinical development services. It overlaps with Celerion in bioanalytical sciences and Phase 1 clinical pharmacology, with strong US-China operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Celerion social profiles

Digital presence

Celerion compliance and trust

Trust signal

Compliance1 record

Celerion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celerion leadership team

Management profile

Number of profiles

Profiles5 records

Celerion funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celerion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celerion

What does Celerion do?

Celerion is a contract research organization (CRO) providing early-phase clinical pharmacology and bioanalytical sciences services for pharmaceutical and biotechnology drug development programs. The company operates integrated clinical research units and laboratory facilities delivering first-in-human studies, dose-escalation trials, bioanalytical method development and validation, sample analysis, and specialized cardiovascular safety assessment including ECG and Holter monitoring.

Is Celerion a public or private company?

Celerion is a private company. It is classified as private equity controlled and is currently operating.

When was Celerion founded?

Celerion was founded in 2010. It employs 1,001 to 5,000 people.

Where is Celerion based?

Celerion is headquartered in Lincoln, United States, in the North America region.

How does Celerion make money?

One revenue line is on record: clinical Research Services.

Who are Celerion's main competitors?

Broad incumbents on record are IQVIA, Labcorp Drug Development (formerly Covance), ICON plc, Parexel International and Syneos Health. Direct peers are Charles River Laboratories, Worldwide Clinical Trials and Medpace. Emerging players are BioAgilytix Labs and Frontage Laboratories.

Does Celerion have an API?

No public API is recorded for Celerion.

What industry is Celerion in?

Celerion's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmafileCelerion expands Swiss bioanalytical laboratory capacityCelerion expanded its Zurich bioanalytical laboratory to increase capacity for drug development, adding staff and new technologies for gene therapies and biosimilars. The lab supports pharmacokinetic, immunogenicity, and biomarker assays, integrated with UK and US clinical units. The facility is now fully operational, aiming to accelerate new medicine development.citybizH.I.G. Capital Sells Celerion for $1.8 Billion as Exit Activity AcceleratesH.I.G. Capital has completed the sale of Celerion Holdings Inc. to funds affiliated with THL Partners in a transaction valued at $1.8 billion, marking a major exit for the firm's Advantage strategy. The sale is part of a broader series of realizations by H.I.G. Advantage, which has completed three exits since Q4 2025 generating more than $4.5 billion in combined enterprise value. Celerion is a global contract research organization specializing in clinical pharmacology and early-stage drug development services, serving pharmaceutical and biotechnology clients through facilities across North America, Europe, and Asia.Pulse 2.0H.I.G. Capital Completes $1.8 Billion Sale Of Celerion Amid Continued Exit MomentumH.I.G. Capital announced the completion of the sale of Celerion Holdings to funds affiliated with THL Partners in a transaction valued at approximately $1.8 billion. The deal represents the latest exit from H.I.G. 's Advantage strategy, and combined with recent sales of St. Croix and United Flow Technologies, the three transactions represent more than $4.5 billion in aggregate enterprise value. H.I.G. Capital noted that these exits demonstrate the platform's ability to generate liquidity and returns for investors despite a challenging environment for mergers and acquisitions and private equity exits.PeprofessionalTHL Closes Flagship Fund XTHL Partners closed its flagship fund THL Equity Fund X LP with $6.35 billion in capital from existing and new investors. The firm has now raised over $50 billion in equity capital since 1974. THL also agreed to acquire Celerion, a clinical research services provider.Pulse 2.0Celerion: Majority Investment From THL Partners To Advance Clinical Pharmacology And Bioanalytical InnovationCelerion, a Lincoln, Nebraska-based clinical pharmacology and bioanalytical sciences company with more than 50 years of operations, has received a majority investment from THL Partners, a private equity firm focused on middle-market growth companies. The transaction, expected to close in 2026 through THL's Fund IX, will support Celerion's expansion of clinical and bioanalytical capabilities serving pharmaceutical and biotechnology partners. THL Partners brings over 25 years of pharma services investment experience and sees Celerion's integrated clinical and laboratory model as a differentiated platform well-positioned for the growing complexity of drug development.FinSMEsCelerion Receives Investment From THL PartnersCelerion, a clinical pharmacology and bioanalytical sciences company, received an undisclosed investment from THL Partners. The company will use the funds to support growth, expand clinical and bioanalytical capabilities, and advance work for pharmaceutical and biotechnology partners.FinTech FuturesCelerion Announces Majority Investment from THL PartnersCelerion, a global provider of clinical pharmacology and bioanalytical sciences, announced a majority investment from THL Partners, a private equity firm specializing in middle-market growth companies. The investment aims to expand Celerion's clinical and bioanalytical capabilities and support pharmaceutical and biotechnology partners in advancing new therapies through early-phase clinical development. The transaction is expected to close in 2026, subject to customary closing conditions.AijournH.I.G. Capital Announces the Sale of CelerionH.I.G. Capital has signed a definitive agreement to sell Celerion Holdings, Inc., a clinical research organization specializing in clinical pharmacology and bioanalytical sciences, to funds affiliated with THL Partners. Celerion, headquartered in Lincoln, Nebraska with facilities in Phoenix, Zurich, and Belfast, was acquired by H.I.G. in November 2022 and has since expanded its clinical and laboratory footprint through strategic investments. Financial terms of the transaction were not disclosed.PR NewswireH.I.G. Capital Announces the Sale of CelerionH.I.G. Capital announced the signing of a definitive agreement to sell its portfolio company Celerion Holdings, a clinical research organization specializing in clinical pharmacology and bioanalytical sciences, to THL Partners. H.I.G. acquired Celerion in November 2022 and during its ownership supported strategic investments across commercial, operational, and technology initiatives that drove exceptional growth and expanded the company's clinical and laboratory footprint. Financial terms of the transaction were not disclosed.AxiosTHL to acquire majority stake in Celerion for $1.8BTHL Partners is acquiring a majority stake in the pharma services company Celerion from H.I.G. for $1.8 billion, according to Axios Pro. The transaction reflects continued private equity appetite for pharma services as biotech funding rebounds and more-complex drugs come to market. The deal represents a significant bet on the growing demand for clinical research services in the pharmaceutical sector.